Phase I Clinical Trial of a Therapeutic for Gram Negative Bacteria Infection
$2,675,212N01FY2021AINIH
Dynport Vaccine Company, Llc, Frederick MD
Investigators
Abstract
The Phase I Clinical Trial Units provide a vehicle for the investigation of new therapeutic agents for the treatment of infectious disease.
View original record on NIH RePORTER →